-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In this day and age, with many new therapies showing promise in improving SLE outcomes, HCQ still retains its central role in therapy and is recommended for all SLE patients as long as there are no contraindications to its us.
The mechanism by which HCQ exerts its therapeutic effect on the SLE disease spectrum is only partially understood, despite years of clinical experience with this dru.
The results of this study are similar to previously reported cross-sectional data in which ILE patients treated with HCQ had lower expression levels of type I IFN-inducible gene.
These new insights into the mechanism and clinical efficacy of HCQ raise the question of whether its disease-modifying potential deserves more respec.
The role of HCQ in preventing SLE demonstrates a hypothetical pattern regarding the development of SLE in high-risk populations:
Another possible reason for the newly discovered role of HCQ is the focus on the early or preclinical stages of SLE rather than in patients with established diseas.
Current estimates are that about half of SLE patients have mild disease, and less than half of them are receiving HC.
To improve outcomes in SLE, further insights into the underlying mechanisms and development of biomarkers to target their use are require.
Reference: Olsen NJ, Karp D.
